Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels

Documenti analoghi

• Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
  di: Mihaylova, B, et al.
  Pubblicazione: (2005)
• Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
  di: Mihaylova, B, et al.
  Pubblicazione: (2005)
• Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
  di: Mihaylova, B, et al.
  Pubblicazione: (2006)
• Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study
  di: Mihaylova, B, et al.
  Pubblicazione: (2024)
• The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
  di: Kent, S, et al.
  Pubblicazione: (2016)